Literature DB >> 23827477

Non-alcoholic steatohepatitis: a microbiota-driven disease.

Alexander R Moschen1, Susanne Kaser, Herbert Tilg.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) has emerged as a major health problem worldwide. Whereas overnutrition and obesity are crucially involved in the development of a simple fatty liver, it remains unclear why approximately 10% of all affected individuals develop the 'inflammatory' phenotype so-called non-alcoholic steatohepatitis (NASH). A link between the intestinal microbiota and the development of obesity and its metabolic consequences including NAFLD is becoming clearer. First clinical, but especially experimental, studies are suggesting that microbiotal factors are driving forces of hepatic steatosis and inflammation that involve Toll-like receptors and proinflammatory cytokines such as tumor necrosis factor-α (TNFα). Future studies focused on deciphering how manipulation of the gut microbiota might prove beneficial for patients with NAFLD are warranted.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  adipocytokines; inflammation; insulin resistance; microbiota; non-alcoholic steatohepatitis

Mesh:

Substances:

Year:  2013        PMID: 23827477     DOI: 10.1016/j.tem.2013.05.009

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  52 in total

1.  Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.

Authors:  Saleh Daher; Namma Lev Cohen; Muhammad Massarwa; Mahmud Mahamid; Mira Nasser; Wadi Hazou; Rani Oren; Rifaat Safadi; Tawfik Khoury
Journal:  PLoS One       Date:  2018-11-30       Impact factor: 3.240

Review 2.  Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.

Authors:  Irina A Kirpich; Luis S Marsano; Craig J McClain
Journal:  Clin Biochem       Date:  2015-07-04       Impact factor: 3.281

Review 3.  Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.

Authors:  Chiara Saponaro; Melania Gaggini; Amalia Gastaldelli
Journal:  Curr Diab Rep       Date:  2015-06       Impact factor: 4.810

Review 4.  Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome.

Authors:  Christoph Grander; Felix Grabherr; Alexander R Moschen; Herbert Tilg
Journal:  Visc Med       Date:  2016-09-16

Review 5.  Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Authors:  Gyorgy Baffy
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

Review 6.  Molecular and cellular mechanisms of liver fibrosis and its regression.

Authors:  Tatiana Kisseleva; David Brenner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-30       Impact factor: 46.802

Review 7.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.

Authors:  Junli Ma; Qihang Zhou; Houkai Li
Journal:  Nutrients       Date:  2017-10-16       Impact factor: 5.717

Review 8.  Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver.

Authors:  Megan J Reiniers; Rowan F van Golen; Thomas M van Gulik; Michal Heger
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 9.  Gut microbiome and metabolic diseases.

Authors:  Shinji Fukuda; Hiroshi Ohno
Journal:  Semin Immunopathol       Date:  2013-11-06       Impact factor: 9.623

Review 10.  Translational approaches: from fatty liver to non-alcoholic steatohepatitis.

Authors:  Natalia Rosso; Norberto C Chavez-Tapia; Claudio Tiribelli; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.